Dec 08, 2020 / 09:15PM GMT
Operator
Welcome to the Phase I data for RP-A501 gene therapy for Danon Disease conference call. My name is Adrian, and I'll be your operator for today's call. (Operator Instructions)
I'll now turn the call over to Claudine Prowse, Senior Vice President of Strategy and Corporate Development. You may begin.
Claudine Prowse - Rocket Pharmaceuticals, Inc. - Senior VP of Strategy and Head of IR & Corporate Development
Thank you so much. Good evening, everyone, and thanks for joining us as we provide, for the first time, clinical results from our Phase I trial from our gene therapy program for Danon Disease. This is Claudine Prowse. I'm Senior Vice President of Strategy and Corporate Development at Rocket. And I'm joined by several members of the Rocket leadership team today, including CEO and President, Dr. Gaurav Shah; Kinnari Patel, our Chief Operating Officer; Dr. Jonathan Schwartz, our Chief Medical Officer; Dr. Jose Trevejo, Senior Vice President and Global Program Head of our AAV Program; and Dr. Brian Beard, Associate Vice President of CMC.
We
Rocket Pharmaceuticals, Inc. - Special Call Transcript
Dec 09, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers